首页> 外文会议>World biomaterials congress >Combining hepatitis B surface antigen (HBsAg) with anthrax (rPA) for a single oral vaccine
【24h】

Combining hepatitis B surface antigen (HBsAg) with anthrax (rPA) for a single oral vaccine

机译:将乙型肝炎表面抗原(HBsAg)与炭疽(RPA)结合用于单个口腔疫苗

获取原文

摘要

Vaccination has not only become vital but a lot of revolutionary changes are being observable in the field of vaccine delivery. Vaccine antigens administered by the oral route are often degraded during gastrointestinal transit. Bile salt stabilized vesicles i.e. bilosomes are found to be effective in preventing antigen degradation and enhance mucosal penetration. The aim of the present work was to prepare a combination vaccine system against hepatitis-B (HBsAg) and anthrax(rPA). Oral immunization induces both mucosal and systemic immune responses, whereas mucosal responses are not generally observed following systemic immunization. Bilosomes provide needle free, painless approach for immunization, thereby increasing patient compliance and consequently increasing vaccination coverage. Bilosomes containing HBsAg and rPA were prepared by a lipid cast film method. Antigen loaded bilosomes were characterized in-vitro for their shape, size, percent antigen entrapment and stability. Fluorescence microscopy was carried out to confirm the uptake of bilosomes. The in-vivo study comprised of estimation of IgG response in serum and sIgA in various body secretions using specific ELISA. Bilosomes formed were multilamellar and were stable in gastric and intestinal fluids. Fluorescence microscopy suggested that bilosomes were taken up by the gut associated lymphoid tissues. In-vivo data demonstrates that bilosomes produced both systemic as well as mucosal antibody responses upon oral administration at higher dose levels as compared to intramuscular immunization but fail to produce any synergistic effect. Thus, HBsAg potentiates the production anti-rPA antibody. Also measurable slgA in mucosal secretions were observed. Thus, the bilosomes are a promising carrier for oral combination vaccines. This approach could be adapted for human use because the mucosal surfaces are the initial sites of infection and it therefore seems logical to attempt to develop vaccination strategies that evoke appropriate localized responses to counteract the early events of pathogenesis.
机译:疫苗接种不仅变得至关重要,而且在疫苗交付领域中可以观察到很多革命性的变化。通过口腔途径施用的疫苗抗原通常在胃肠过境过程中降解。胆汁盐稳定囊泡I.E.E.E.E.E.E.E.Semosomes有效地预防抗原降解和增强粘膜渗透。本作本作的目的是制备针对肝炎-B(HBsAg)和炭疽(RPA)的组合疫苗系统。口服免疫诱导粘膜和全身免疫应答,而在全身免疫后通常不观察到粘膜反应。双染色体提供针自由,无痛的免疫方法,从而提高患者的顺应性,从而提高疫苗接种覆盖率。通过脂质铸膜法制备含有HBsAg和RPA的比蛋白酶。抗原加载的双染色剂在体外表征它们的形状,尺寸,抗原截留和稳定性。进行荧光显微镜检查以确认脱椎素的吸收。使用特定ELISA的各种身体分泌物中血清和SIGA中IgG反应的估计的体内研究。形成的比菌丝是多岩石,在胃和肠液中稳定。荧光显微镜表明,肠道相关淋巴组织占用了双菌。体内数据表明,与肌肉内免疫相比,双染色剂在口服施用时,在口服施用时产生的粘膜抗体反应,但不能产生任何协同效应。因此,HBsAg增强了生产抗RPA抗体。还观察到粘膜分泌中可测量的SLGA。因此,双偏体是用于口腔组合疫苗的有望的载体。这种方法可以适用于人类使用,因为粘膜表面是感染的初始位点,因此似乎试图开发唤起适当的局部反应来抵消发病机制早期事件的疫苗接种策略来逻辑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号